UK clinical trials - updated daily from ClinicalTrials.gov
Understand the key differences between lung cancer (nsclc) and mesothelioma clinical trials and research opportunities
The third most common cancer in the UK with strong biomarker-driven trial activity. EGFR, ALK, KRAS, and PD-L1 testing now guides treatment and trial eligibility.
Strongly linked to asbestos exposure, with UK having one of the highest global rates. Trials focus on immunotherapy combinations and novel chemotherapy approaches.
Lung cancer has far more trials driven by molecular subtyping. Mesothelioma has fewer but highly targeted trials, often specific to histological subtype (epithelioid vs sarcomatoid).
Search our database of 29,000+ UK clinical trials matched to your condition and profile
Browse Disease PathwaysData sourced from ClinicalTrials.gov. Trial counts are approximate and updated regularly.
TrialConnect is a trading name of Clinical Vendor Compare Limited.
